Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 18.9% in March

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) saw a large decrease in short interest in March. As of March 13th, there was short interest totaling 13,996 shares, a decrease of 18.9% from the February 26th total of 17,248 shares. Based on an average trading volume of 3,198 shares, the short-interest ratio is currently 4.4 days. Currently, 0.0% of the company’s stock are sold short.

Institutional Investors Weigh In On Molecular Partners

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors own 26.55% of the company’s stock.

Molecular Partners Stock Performance

MOLN traded down $0.26 on Monday, hitting $3.79. The company had a trading volume of 2,313 shares, compared to its average volume of 4,572. The stock has a market capitalization of $153.08 million, a price-to-earnings ratio of -1.91 and a beta of 1.03. The stock has a fifty day moving average price of $4.57 and a 200-day moving average price of $4.23. Molecular Partners has a 12-month low of $3.36 and a 12-month high of $5.36.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). Analysts forecast that Molecular Partners will post -1.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on MOLN shares. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Molecular Partners in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research note on Monday, December 22nd. TD Cowen reissued a “buy” rating on shares of Molecular Partners in a research note on Monday, March 16th. Finally, JPMorgan Chase & Co. lowered their target price on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a report on Monday, December 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.38.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.